Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants

The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma patients carrying a mutation in codon V600 of the BRAF gene exclusively. However, BRAF mutations outside the V600 codon may occur in a small percentage of melanomas. Although these rare variants may cause...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-07, Vol.24 (15), p.12285
Main Authors: Scaini, Maria Chiara, Piccin, Luisa, Bassani, Davide, Scapinello, Antonio, Pellegrini, Stefania, Poggiana, Cristina, Catoni, Cristina, Tonello, Debora, Pigozzo, Jacopo, Dall'Olmo, Luigi, Rosato, Antonio, Moro, Stefano, Chiarion-Sileni, Vanna, Menin, Chiara
Format: Article
Language:English
Subjects:
Activities of daily living
Algorithms
Antimitotic agents
Antineoplastic agents
Biopsy
Cancer
Care and treatment
Codon
Drug approval
Drug therapy
FDA approval
Gene mutations
Instrument industry
Kinases
Ligands
Melanoma
Metastasis
Mutation
Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Food and Drug Administration (FDA) has approved MAPK inhibitors as a treatment for melanoma patients carrying a mutation in codon V600 of the BRAF gene exclusively. However, BRAF mutations outside the V600 codon may occur in a small percentage of melanomas. Although these rare variants may cause B-RAF activation, their predictive response to B-RAF inhibitor treatments is still poorly understood. We exploited an integrated approach for mutation detection, tumor evolution tracking, and assessment of response to treatment in a metastatic melanoma patient carrying the rare p.T599dup B-RAF mutation. He was addressed to Dabrafenib/Trametinib targeted therapy, showing an initial dramatic response. In parallel, in-silico ligand-based homology modeling was set up and performed on this and an additional B-RAF rare variant (p.A598_T599insV) to unveil and justify the success of the B-RAF inhibitory activity of Dabrafenib, showing that it could adeptly bind both these variants in a similar manner to how it binds and inhibits the V600E mutant. These findings open up the possibility of broadening the spectrum of BRAF inhibitor-sensitive mutations beyond mutations at codon V600, suggesting that B-RAF V600 WT melanomas should undergo more specific investigations before ruling out the possibility of targeted therapy.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241512285